Differences in tumor cell proliferation, HLA DR expression and lymphocytic infiltration in various types of thyroid carcinoma

Summary

The proliferative activity of various thyroid carcinoma forms (papillary, follicular, medullary, anaplastic) was investigated using two second generation antibodies against Ki-67 that can be used on paraffin-embedded sections. Poorly-differentiated carcinomas had a higher proliferation than well-differentiated forms. Papillary carcinoma stained significantly more often with either antibody than follicular carcinoma. A solid growth pattern correlated with high Ki-67 expression while an increase in follicular elements and a high amount of psammoma bodies coincided with lower proliferation.

HLA class II expression and infiltrating lymphocytes are prerequisites for an immune defense against cancer. In this study, HLA DR was increased in poorly-differentiated carcinomas, especially in the anaplastic type. The increase in HLA DR was correlated with Ki-67 positivity. On tumor-infiltrating lymphocytes, HLA DR was well expressed in papillary carcinoma and relatively poorly expressed in follicular carcinoma, but there was no significant correlation with carcinoma type or morphological parameters. CD 45 R0, which might recognize memory cells, was found mostly in anaplastic and papillary carcinomas, and correlated well with HLA DR expression. These findings imply that an active but variable immune response is present in thyroid carcinoma.

Thyroid carcinoma - Ki-67 - HLA DR expression - Tumor infiltrating lymphocytes - CD 45 receptor

References

• 1 Adams T E, Bodmer J G, Bodmer W F. Production and characterization of monoclonal antibodies recognizing the α-chain subunits of human Ia alloantigens.  Immunology. 1983;  50 613-624
• 2 Baker J R, Fosso C K. Immunological aspects of cancers arising from thyroid follicular cells.  Endocrine Rev. 1993;  14 729-746
• 3 Betterle C, Presotto F, Caretto A, Pelizzo M R, Pedini B, Girelli M E, Busnardo B . Expression of class I and II human leukocyte antigens by thyrocytes and lymphocytic infiltration on human thyroid tumors.  Cancer. 1991;  67 977-983
• 4 Carr K, Heffess C, Jin L, Lloyd R V. Immunohistochemical analysis of thyroid carcinomas utilizing antibodies to p53 and Ki-67.  Appl Immunohistochem. 1993;  1 201-207
• 5 Catálfamo M, Serradell L, Roura-Mir C, Kolkowski E, Sospedra M, Vives-Pi M, Vargas-Nieto F, Pujol-Burrell R, Jaraquemada D . HLA-DM and invariant chain are expressed by thyroid follicular cells, enabling the expression of compact DR molecules.  Int Immunol. 1999;  11 269-277
• 6 Cattoretti G, Becker M HG, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J . Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.  J Pathol. 1992;  168 357-363
• 7 Feinmesser M, Stern S, Mechlis-Frish S, Lubin E, Feinmesser R, Kristt D . HLA-DR expression and lymphocytic infiltration in metastatic and non-metastatic papillary carcinoma of the thyroid.  Eur J Surg Oncol. 1996;  22 494-501
• 8 Fisfalen M E, Franklin W A, De Groot L J, Cajulis R S, Soltani K, Ryan M, Jones N . Expression of HLA ABC and HLA DR antigens in thyroid neoplasia and correlation with mononuclear leukocyte infiltration.  J Endocrinol Invest. 1990;  13 41-48
• 9 Goldsmith N K, Dikman S, Bermas B, Davies T F, Roman S H. HLA class II antigen expression and the autoimmune thyroid response in patients with benign and malignant thyroid tumors.  Clin Immunol Immunopathol. 1988;  48 161-173
• 10 Grüneberg U, Rich T, Roucard C, van Ham S M, Charron D, Trowsdale J . Two widely used anti-DR α monoclonal antibodies bind to an intracellular C-terminal epitope.  Human Immunol. 1997;  53 34-38
• 11 Hedinger C, Williams E D, Sobin L H. (eds) .Histological typing of thyroid tumors. Second Edition. Springer, Berlin, Heidelberg 1988
• 12 Herrmann G, Schumm-Draeger P-M, Müller C, Atai E, Wenzel B, Fabian T, Usadel K H, Hübner K . T lymphocytes, CD 68-positive cells and vascularisation in thyroid carcinomas.  J Cancer Res Clin Oncol. 1994;  120 651-656
• 13 Juhasz F, Boros P, Szegedi G, Balazs G, Suranyi P, Kraszits E, Stenszky V, Farid N R. Immunogenetic and immunologic studies of differentiated thyroid cancer.  Cancer. 1989;  63 1318-1326
• 14 Justement L B. The role of CD 45 in signal transduction.  Adv Immunol. 1997;  66 1-65
• 15 Katoh R, Bray C E, Suzuki K, Komiyama A, Hemmi A, Kawaoi A, Oyama T, Sugai T, Sasou S . Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1.  Hum Pathol. 1995;  26 139-146
• 16 Katsumoto Y, Monden T, Takeda T, Haba A, Ito Y, Wakasugi E, Wakasugi T, Sekimoto M, Kobayashi T, Shiozaki H, Shimano T, Monden M . Analysis of cytotoxic activity of the CD4+ T lymphocytes generated by local immunotherapy.  Br J Cancer. 1996;  73 110-116
• 17 Key G, Larsen Petersen J, Becker M HG, Duchrow M, Schlüter C, Askaa J, Gerdes J . New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections.  J Clin Pathol. 1993;  46 1080-1084
• 18 Lahat N, Rahat M A, Sadeh O, Kinarty A, Kraiem Z . Regulation of HLA-DR and costimulatory B7 molecules in human thyroid carcinoma cells: Differential binding of transcription factors to the HLA-DR α promoter.  Thyroid. 1998;  8 361-369
• 19 Lloyd R V, Johnson T L, Blaivas M, Sisson J C, Wilson B S. Detection of HLA-DR antigens in paraffin-embedded thyroid epithelial cells with a monoclonal antibody.  Am J Pathol. 1985;  120 106-111
• 20 Loh K C, Greenspan F S, Dong F, Miller T R, Yeo P P. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma.  J Clin Endocrinol Metab. 1999;  84 458-463
• 21 Lucas-Martin A, Foz-Sala M, Todd I, Bottazzu G F, Pujol-Borrell R. Occurrence of thyrocyte HLA class II expression in a wide variety of thyroid diseases: relationship with lymphocytic infiltration and thyroid antibodies.  J Clin Endocrinol Metab. 1988;  66 367-375
• 22 Matsubayashi S, Kawai K, Matsumoto Y, Mukuta T, Morita T, Hirai K, Matsuzuka F, Kakudoh K-I, Kuma K, Tamai H . The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland.  J Clin Endocrinol Metab. 1995;  80 3421-3424
• 23 Matsuoka N, Eguchi K, Kawakami A, Tsuboi M, Nakamura H, Kimura H, Ishikawa N, Ito K, Nagataki S . Lack of B7-1/BB1 and B7-2/B70 expression on thyrocytes of patients with Graves' disease. Delivery of costimulatory signals from bystander professional antigen-presenting cells.  J Clin Endocrinol Metab. 1996;  81 4137-4143
• 24 Poppema S, Lai R, Visser L . Monoclonal antibody OPD 4 is reactive with CD45R0, but differs from UCHL1 from the absence of monocyte reactivity.  Am J Pathol. 1991;  139 725-729
• 25 Resnick M B, Schacter P, Finkelstein Y, Kellner Y, Cohen O . Immunohistochemical analysis of p27/kip 1 expression in thyroid carcinomas.  Mod Pathol. 1998;  11 735-739
• 26 Rosai J, Carcangiu M L, DeLellis R A. Tumors of the thyroid gland. Armed Forces Institute of Pathology, Washington DC 1992
• 27 Scholzen T, Gerdes J . The Ki-67 protein: From the known and the unknown.  J Cell Physiol. 2000;  182 311-322
• 28 Sreelekha T T, Pradeep V M, Vijayalakshmi K, Belthazar A, Chellam V G, Nair M B, Pillai M R. In situ apoptosis in the thyroid.  Thyroid. 2000;  10 117-122
• 29 Yoshida A, Nakamura Y, Imada T, Asaga T, Shimizu A, Harada M . Apoptosis and proliferative activity in thyroid tumors.  Jpn J Surg. 1999;  29 204-208
• 30 Yoshino T, Mukuzono H, Aoki H, Takahashi K, Takeuchi T, Kubonishi I, Ohtsuki Y, Motoi M, Akagi T . A novel monoclonal antibody (OPD 4) recognizing a helper/inducer T cell subset.  Am J Pathol. 1989;  134 1339-1346